Berfu Nur Yigit

Berfu Nur Yigit

Auto-generated profile, based on publicly available information

Berfu Nur Yigit

Koc University 4 Department of Molecular Biology and Genetics İstanbul

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
DZDonia Zaidi
Donia Zaidi
KCKaviya Chinnappa
Kaviya Chinnappa
BYBerfu Nur Yigit
Berfu Nur Yigit
VVValeria Viola
Valeria Viola
CDCarmen Cifuentes Diaz
Carmen Cifuentes Diaz
FFFiona FRANCIS
Fiona FRANCIS
Subcortical heterotopia is a cortical malformation associated with epilepsy, intellectual disability, and an excessive number of cortical neurons in the white matter. Echinoderm microtubule-associated protein like 1 (EML1) mutations lead to subcortical heterotopia, associated with abnormal radial glia positioning in the cortical wall, prior to malformation onset. This perturbed distribution of proliferative cells is likely to be a critical event for heterotopia formation; however, the underlying mechanisms remain unexplained. This study aimed to decipher the early cellular alterations leading to abnormal radial glia. In a forebrain conditional Eml1 mutant model and human patient cells, primary cilia and centrosomes are altered. Microtubule dynamics and cell cycle kinetics are also abnormal in mouse mutant radial glia. By rescuing microtubule formation in Eml1 mutant embryonic brains, abnormal radial glia delamination and heterotopia volume were significantly reduced. Thus, our new model of subcortical heterotopia reveals the causal link between Eml1’s function in microtubule regulation and cell position, both critical for correct cortical development.

1 January 2021 in All Life
Verified
Journal Article
Open access
TATimucin Avsar
Timucin Avsar
BYBerfu Nur Yigit
Berfu Nur Yigit
GTGizem Turan
Gizem Turan
DADeniz Altunsu
Deniz Altunsu
SCSeyma Calis
Seyma Calis
MAMelih Acar
Melih Acar
Cell cycle inhibitors are considered as hallmark strategy for cancer treatment due to their relatively higher selectivity and efficacy on various cancer types in comparison to cytotoxic agents. Small molecules target dividing cells in G1/S, G2 or M phases of cells to arrest and eventually trigger cancer cells to enter apoptosis and/or inhibit tumor growth. Cell cycle arrest at G2/M phase is a widely used approach to inhibit proliferating cancer cells. We report a novel angiotensin II receptor type I (AT1R) antagonist that also targets CDC2 (CDK1) kinase thereby showing a putative anti-cancer activity. The molecule named 19D was tested in various cancer cell lines at different concentrations. Molecular mechanisms of action triggered by the treatment of 19D were investigated for anti-cancer activity at cellular and molecular level. 19D molecule showed a potent cell cycle arrest with anti-proliferation activity. Cells treated with 19D showed nuclear deteriorations and apoptotic induction on cancer cells. Moreover, the mechanism of cell cycle inhibition was revealed as G2/M arrest via suppressing the CDC2 kinase cell cycle check point inhibitor. In conclusion, 19D (an AT1R antagonist) is a novel small molecule/imidazolone derivative which has been demonstrated as a fairly potent anti-cancer molecule. Abbreviations: AT1R: angiotensin II receptor type 1; BSA: bovine serum albumine; CDC2: cyclin-dependent kinase 1; CDK: cyclin-dependent kinase; DMEM: Dulbecco’s modified eagle medium; DMSO: dimethylsulfoxide; EDTA: ethylenediaminetetraacetic acid; FBS: fetal bovine serum; HBSS: Hank’s balanced salt solution; IC50: half maximal inhibitory concentration; PBS-T: phosphate buffered saline – TritonX; PBS: phosphate buffered saline; PDB: protein data bank; SDS: sodium dodecyl sulfate; TBS-T: Tris buffered saline – TritonX